EVIDENCE PROFILE / PUBLISHED
TB-500
A common name for an acetylated seven-amino-acid fragment of thymosin beta-4; it is not full-length thymosin beta-4, and human findings for the full molecule do not transfer to TB-500.
Evidence at a glance
- Human
- None foundNo human study of this fragment found in the sources reviewed.
- Animal/cell
- LimitedFew studies of the fragment itself: a cell assay and animal breakdown work.
- Approved medicine
- None foundScope: the Canadian and U.S. sources reviewed.
Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
PREPPY BOY ASKS
“Same neighbourhood is not same molecule. Forty-three residues and seven residues are different addresses—and the acetyl group matters too.”
TB-500 is where an evidence review must begin with identity. Similar names have been used for different materials, and much of the human story repeated online belongs to full-length thymosin beta-4—not this fragment.
Identity and established aliases
FDA's 2026 evaluation describes TB-500 free base as Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH (Ac-LKKTETQ), a synthetic N-terminally acetylated fragment corresponding to residues 17–23 of the 43-amino-acid protein thymosin beta-4. TB-500 is a common name, not a USAN, and FDA found it used for different salts, derivatives, and even different active moieties.
TB-500 is not a synthetic copy of full-length thymosin beta-4. Nor can results for non-acetylated LKKTETQ automatically be applied: acetylation changes charge, hydrophobicity, size, stability, and potentially biological activity. The catalogue leaves sequence unspecified; this profile therefore links by label only and does not validate catalogue identity.
Why researchers study it
The LKKTET segment overlaps an actin-binding region of thymosin beta-4, leading to hypotheses about actin buffering, cell movement, angiogenesis, and wound repair. FDA found that whether actin binding explains any fragment activity remains unresolved.
A 2024 analytical study tracked TB-500 metabolism in human serum systems and rats, then compared scratch-assay activity. The parent fragment did not significantly close the scratch under the tested condition; one metabolite produced a small signal. That finding raises a mechanistic question rather than demonstrating wound healing in a person.
Approved medicines and investigational uses
No TB-500 active-ingredient record was returned by Health Canada's Drug Product Database under the reviewed name. FDA states that TB-500 free base and acetate are not components of an FDA-approved drug. These searches do not establish worldwide status.
FDA evaluated nominated compounded use for wound healing. It found no article in which TB-500 was administered to humans. Human trials of topical, ophthalmic, or intravenous full-length thymosin beta-4 are research on a different molecule and formulation and are included here only to make that non-equivalence explicit.
What human studies show
No human TB-500 administration study was found in FDA's search. Therefore, there is no direct human evidence in the reviewed sources for wound healing, recovery, pharmacokinetics, or clinical safety of TB-500 free base or acetate.
A randomized venous-ulcer study used topical full-length 43-amino-acid thymosin beta-4, and a phase 1 study used intravenous NL005, a recombinant 44-amino-acid thymosin-beta-4 construct. Those findings cannot be assigned to Ac-LKKTETQ, to a salt with uncertain identity, or to a catalogue vial.
What cells and animal studies show
Non-acetylated LKKTETQ has been studied in aged-mouse wound models, but FDA cautioned that those results cannot be directly extrapolated to acetylated TB-500. The 2024 parent-fragment scratch assay was negative at the tested concentration, while a metabolite showed a small effect. Animal pharmacokinetic work shows rapid breakdown into smaller peptides; it does not establish a therapeutic effect.
Popular claims and evidence limits
Popular claims span tendon and muscle repair, inflammation, endurance, hair growth, and cardiovascular or neurological effects. FDA found no human TB-500 evidence supporting these claims. Many summaries silently substitute thymosin beta-4 studies, which answers a different question.
What remains uncertain
Basic uncertainties include which chemical form a labelled product contains, whether the reference standard matches it, pharmacology of the parent versus metabolites, human exposure, dose-response, and short- and long-term toxicity. FDA highlighted aggregation, peptide-related impurities, immunogenicity, sterility, and endotoxin as unresolved concerns for proposed injectable formulations.
